SRS/SRT & Immune Activation for Systemic Cancers
PetCure Oncology, in collaboration with Varian Medical Systems, is currently accepting animals into a clinical trial to study the immune response of dogs that receive stereotactic radiation (SRS/SRT) to treat osteosarcoma, oral malignant melanoma, sinus/nasal tumors, or thyroid carcinoma. All four of these tumor types are known to have the potential to spread (metastasize) to other parts of the body.
This clinical trial was launched to evaluate specific immune cells found in the blood. These immune cells have been found to impact survival in people across several tumor types that also have metastatic potential. Early data collected by PetCure Oncology as well as other investigators suggests that SRS/SRT in dogs may have a positive effect on the immune cells responsible for attacking cancer, leading to longer survival times than a traditional treatment course centered around surgical tumor removal including amputation. One hypothesis for this is that SRS/SRT not only treats the primary tumor, but it may also modulate the anti-tumor immune response in a manner that inhibits the spread of the cancer. The purpose of this trial is to test this theory.
Enrollment in this trial is for dogs undergoing SRS/SRT for treatment of qualified cases of osteosarcoma, oral malignant melanoma, sinus/nasal tumors, or thyroid carcinoma. It involves participation in four (4) scheduled blood draws extending 1-month post-treatment. All trial-related blood draws will be free of charge, and pet owners will be provided $2,000 in compensation towards their treatment.
If you are the owner or veterinarian of a dog with diagnosed or suspected osteosarcoma, oral malignant melanoma, sinus/nasal tumors, or thyroid carcinoma, contact ClinicalTrials@PetCureOncology.com or call 833-PET-HERO for additional details.